Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Ascension Orthopedics' Titan

This article was originally published in The Gray Sheet

Executive Summary

Modular total shoulder system gains FDA market go-ahead, announced Sept. 2. The device is designed to provide multiple shoulder arthroplasty surgery solutions in a single implant system, the company explains. It offers a bone-preserving option for patients needing total or hemi-shoulder arthroplasty, allows surgeons to select distal stems and proximal bodies that best match patients' anatomy and bone quality, and includes 26 humeral head sizing options

You may also be interested in...

Integra Enters Shoulder Market, Builds Upper Extremity Biz Via Ascension Purchase

Integra LifeSciences will expand its orthopedic extremity implant offerings and bolster its upper extremity business in particular while entering the shoulder market for the first time with its $65 million acquisition of Ascension Orthopedics, announced Sept. 12.

UK Health Service Not Taking Full Advantage Of Digital Self-Care Apps – PAGB Audit

PAGB calls on NHS England to create a self-care section in its NHS App and reinstate its online Apps Library to promote responsible digital self-care in the UK. 

ADCs Propel China Oncology Innovation But PD-1s Still Cast Shadow

Among the newer modalities to tackle cancer, antibody-drug conjugates are fast emerging to rival targeted antibodies and China is fast emerging as a world class source of innovation in the field, as evidenced by a string of recent deals.


Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts